TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Swedish Orphan Biovitrum AB (publ)
Closing information (x1000 EUR)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover | 1,688,488 | 1,518,446 | 1,520,399 |
Financial expenses | 44,661 | 44,393 | 59,975 |
Earnings before taxes | 298,428 | 322,190 | 420,125 |
EBITDA | 546,984 | 560,580 | 681,544 |
Total assets | 4,717,342 | 4,758,138 | 4,810,262 |
Current assets | 1,007,432 | 858,325 | 813,748 |
Current liabilities | 1,335,065 | 856,662 | 1,040,399 |
Equity capital | 2,383,563 | 2,268,820 | 2,013,051 |
- share capital | 15,276 | 16,525 | 16,638 |
Employees (average) | 1,556 | 1,559 | 1,509 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency | 50.5% | 47.7% | 41.8% |
Turnover per employee | 1,085 | 974 | 1,008 |
Profit as a percentage of turnover | 17.7% | 21.2% | 27.6% |
Return on assets (ROA) | 7.3% | 7.7% | 10.0% |
Current ratio | 75.5% | 100.2% | 78.2% |
Return on equity (ROE) | 12.5% | 14.2% | 20.9% |
Change turnover | 293,037 | 26,205 | 100,922 |
Change turnover % | 21% | 2% | 7% |
Chg. No. of employees | -3 | 50 | 174 |
Chg. No. of employees % | 0% | 3% | 13% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.